Amended Statement of Beneficial Ownership (sc 13d/a)

Date : 03/13/2019 @ 6:40PM
Source : Edgar (US Regulatory)
Stock : Albireo Pharma Inc (ALBO)
Quote : 21.0  -0.33 (-1.55%) @ 1:00AM
After Hours
Last Trade
Last $ 21.00 ◊ 0.00 (0.00%)

Amended Statement of Beneficial Ownership (sc 13d/a)


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*


ALBIREO PHARMA, INC.
(Name of Issuer)

Common Stock, par value $0.01 per share
(Title of Class of Securities)

01345P 106
(CUSIP Number)

Charles Sermon
Phase4 Partners Limited
1 Cavendish Place
London W1G 0QF, United Kingdom
Telephone: +44 0 20 3036 0050
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 27, 2019
(Date of Event Which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐


Note . Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See   § 240.13d-7 for other parties to whom copies are to be sent.



*
The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 
 
Phase4 Partners Limited
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
England and Wales
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares 1
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares 1
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 1
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0% 2
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
OO
 
 
 
 


1
Represents shares held by Phase4 Ventures III GP LP ( Phase4 GPLP ) in its capacity as general partner of Phase4 Ventures III LP ( Phase4 III ). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited ( Phase4 GP ). Phase4 GP has appointed Phase4 Partners Limited ( Phase4 Partners ) to act as the manager of Phase4 III. Phase4 Partners ultimately exercises voting and investment power over the securities held by Phase4 GPLP. Dr. Alastair McKinnon, Denise Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Phase4 Partners, Phase4 GP, Phase4 GPLP and Phase4 III may each be deemed to have sole voting and dispositive power over the shares and Dr. McKinnon, Dr. Scots-Knight and Mr. Sermon may each be deemed to have shared voting and dispositive power over the shares.
2
The percentage ownership was calculated based on 11,897,146 shares of common stock outstanding as of the March 1, 2018, as disclosed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by Albireo Pharma, Inc. (the “Issuer”) with the Securities and Exchange Commission on March 27, 2018.


CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 
 
Phase4 Ventures III LP
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
England and Wales
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares 3
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares 3
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 3
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0% 4
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
PN
 
 
 
 


3
See footnote 1.
4
See footnote 2.


CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 
 
Phase4 Ventures III GP LP
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
Scotland
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares 5
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares 5
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 5
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0% 6
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
PN
 
 
 
 


5
See footnote 1.
6
See footnote 2.


CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 
 
Phase4 Ventures III General Partner Limited
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
Scotland
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares 7
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares 7
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 7
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0% 8
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
OO
 
 
 
 


7
See footnote 1.
8
See footnote 2.


CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 
 
Dr. Alastair McKinnon
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
United Kingdom
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares 9
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares 9
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 9
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0% 10
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
IN
 
 
 
 


9
See footnote 1.
10
See footnote 2.


CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 
 
Denise Scots-Knight, Ph.D.
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
United Kingdom
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares 11
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares 11
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 11
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0% 12
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
IN
 
 
 
 


11
See footnote 1.
12
See footnote 2.


CUSIP No. 01345P 106
Schedule 13D
 

1
NAME OF REPORTING PERSON
 
 

Charles Sermon
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
☒ (joint filers)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS
 
 
OO
 
 
 
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
 
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
United Kingdom
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
0 shares
 
 
 
 
8
SHARED VOTING POWER
 
 
0 shares 13
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
0 shares
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0 shares 13
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
0 shares 13
 
 
 
 
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
% 14
 
 
 
 
14
TYPE OF REPORTING PERSON
 
 
IN
 
 
 
 


13
See footnote 1.
14
See footnote 2.


Schedule 13D

This Amendment No. 2 (“Amendment No. 2”) amends the Statement on Schedule 13D first filed with the Securities and Exchange Commission on November 3, 2016, (as amended, the “Schedule 13D”), and is filed by the Reporting Persons with respect to the common stock, par value $0.01 per share (the “Common Stock”), of Albireo Pharma, Inc. (the Issuer ). Capitalized terms used herein but not defined

Item 5.
Interest in Securities of the Issuer.

(a)-(b):

Number of shares of Common Stock beneficially owned:

Phase4 Partners
0 shares
Phase4 III
0 shares
Phase4 GPLP
0 shares
Phase4 GP
0 shares
Dr. Alastair McKinnon
0 shares
Denise Scots-Knight, Ph.D.
0 shares
Charles Sermon
0 shares

Percent of class:

Phase4 Partners Limited
0%
Phase4 Ventures III LP
0%
Phase4 Ventures III GP LP
0%
Phase4 Ventures III General Partner Limited
0%
Dr. Alastair McKinnon
0%
Dr. Denise Scots-Knight
0%
Charles Sermon
0%

The percentage ownership was calculated based on 11,897,146 shares of common stock outstanding as of the March 1, 2018, as disclosed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by Albireo Pharma, Inc. (the “Issuer”) with the Securities and Exchange Commission on March 27, 2018.


Number of shares as to which such person has:

(i)
Sole power to vote or to direct the vote:

Phase4 Partners
0 shares
Phase4 III
0 shares
Phase4 GPLP
0 shares
Phase4 GP
0 shares
Dr. Alastair McKinnon
0 shares
Denise Scots-Knight, Ph.D.
0 shares
Charles Sermon
0 shares

(ii)
Shared power to vote or to direct the vote:

Phase4 Partners
0 shares
Phase4 III
0 shares
Phase4 GPLP
0 shares
Phase4 GP
0 shares
Dr. Alastair McKinnon
0 shares
Denise Scots-Knight, Ph.D.
0 shares
Charles Sermon
0 shares

(iii)
Sole power to dispose or to direct the disposition of:

Phase4 Partners
0 shares
Phase4 III
0 shares
Phase4 GPLP
0 shares
Phase4 GP
0 shares
Dr. Alastair McKinnon
0 shares
Denise Scots-Knight, Ph.D.
0 shares
Charles Sermon
0 shares

(iv)
Shared power to dispose or to direct the disposition of:

Phase4 Partners
0 shares
Phase4 III
0 shares
Phase4 GPLP
0 shares
Phase4 GP
0 shares
Dr. Alastair McKinnon
0 shares
Denise Scots-Knight, Ph.D.
0 shares
Charles Sermon
0 shares


Between January 31, 2018 and May 11, 2018, the Reporting Persons sold 479,894 shares of Common Stock in the aggregate for $15,864,253.89.

Date
Number of Shares of
Common Stock
Price per Share*
Price Range
       
01/31/18
1,200
35.1000
$35.00
$35.18
02/01/18
2,802
35.1790
$35.00
$35.68
02/02/18
1,504
35.0057
$35.00
$35.10
02/05/18
4,397
35.2435
$35.00
$35.97
02/05/18
100
36.2400
$36.24
$36.24
02/06/18
947
35.0000
$35.00
$35.00
02/07/18
10,900
35.1653
$34.50
$35.50
02/07/18
3,800
35.7621
$35.51
$36.00
02/08/18
3,265
34.9687
$34.50
$35.46
02/08/18
6,735
36.1012
$35.88
$36.25
02/09/18
2,366
34.5767
$34.50
$34.66
02/12/18
3,954
35.1117
$34.55
$35.55
02/12/18
16,046
36.1772
$35.81
$36.76
02/13/18
5,068
35.2218
$34.73
$35.73
02/13/18
4,932
36.0705
$35.74
$36.36
02/14/18
9,900
35.6986
$35.02
$36.00
02/14/18
100
36.1500
$36.15
$36.15
02/15/18
9,700
35.6332
$35.16
$36.18
02/15/18
300
36.1767
$36.17
$36.18
02/16/18
5,984
34.8840
$34.50
$35.44
02/20/18
5,617
34.7734
$34.50
$35.21
02/21/18
1,260
34.5998
$34.50
$34.87
02/26/18
4,121
34.7987
$34.50
$35.02
02/27/18
92
34.5000
$34.50
$34.50
02/28/18
200
34.5200
$34.50
$34.54
03/02/18
12,405
34.8597
$34.50
$35.44
03/05/18
5,053
34.7777
$34.50
$35.27
03/06/18
2,936
34.6519
$34.50
$34.89
03/07/18
10,769
34.9047
$34.50
$35.33
03/08/18
400
34.6850
$34.50
$34.81
03/09/18
47
34.5000
$34.50
$34.50
03/12/18
6,761
34.5595
$34.50
$34.89
03/13/18
12,255
35.0308
$34.52
$35.49
03/13/18
7,745
35.9139
$35.54
$35.49
03/14/18
9,189
35.3852
$34.78
$35.77
03/14/18
2600
36.0258
$35.79
$36.14
03/15/18
20,000
35.4025
$34.96
$35.95
03/16/18
15,400
35.4134
$34.70
$35.70
03/16/18
4,600
35.9843
$35.73
$36.25
03/19/18
29,059
36.3784
$35.86
$36.86
03/19/18
466
37.0880
$36.90
$37.60
03/19/18
500
38.056
$37.92
$38.46
03/20/18
4,700
35.1972
$34.84
$35.62
03/20/18
13,636
36.1751
$35.92
$36.50
03/21/18
3,490
34.6079
$34.50
$35.09
03/22/18
500
34.5320
$34.50
$34.60
04/12/18
3,905
34.5003
$34.50
$34.76
04/20/18
2,700
34.5000
$34.50
$34.50
04/23/18
3,614
32.6157
$32.22
$32.98
04/24/18
2,534
32.2880
$32.00
$33.00
05/04/18
24,384
29.1079
$29.00
$29.40
05/04/18
8,901
29.6576
$29.41
$30.41
05/07/18
21,161
29.0413
$29.00
$29.33
05/08/18
45,554
29.0780
$29.00
$29.30
05/09/18
50,000
30.0009
$30.00
$30.24
05/10/18
4,872
31.0206
$31.00
$31.25
05/11/18
44,468
31.0014
$31.00
$31.24


(c) Between February 5, 2019 and February 27, 2019, the Reporting Persons sold 96,321 shares of Common Stock in open market transactions as follows:

Date
Number of Shares of
Common Stock
Price per Share*
Price Range
       
02/05/19
10,000
26.3426
$26.10
$26.74
02/06/19
10,000
26.0652
$26.00
$26.50
02/13/19
8,583
26.0412
$26.00
$26.10
02/14/19
800
26.0000
$26.00
$26.00
02/15/19
10,000
26.0464
$26.00
$26.34
02/19/19
10,000
26.0319
$26.00
$26.27
02/20/19
7,647
26.0000
$26.00
$26.00
02/22/19
10,000
26.0174
$26.00
$26.35
02/25/19
10,000
26.0943
$26.00
$26.50
02/26/19
10,000
25.9642
$25.85
$26.51
02/26/19
2,669
27.4354
$27.30
$27.75
02/27/19
422
26.9170
$26.29
$27.21
02/27/19
6200
27.4158
$27.33
$27.53

*The number of securities reported represent an aggregate number of shares executed by a broker-dealer in multiple market transactions over a range of prices. The price per share reported represents the weighted-average price (without regard to brokerage commissions and fees). The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, the number of shares executed at each separate price within the range.

Except as set forth above, the Reporting Persons have not effected any transactions with respect to the shares of the Common Stock during the past 60 days.

(d) Not applicable.

(e) As of May 11, 2018, the reporting persons ceased to be the beneficial owners of more than five percent of the class of Common Stock of the Issuer.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 13, 2019
PHASE4 PARTNERS LIMITED
     
 
By:
 /s/ Charles Sermon
 
Name: Charles Sermon
 
Title: Director
     
Date: March 13, 2019
PHASE4 VENTURES III LP
     
 
By: Phase4 Partners Limited, its Manager
     
 
By:
 /s/ Charles Sermon
 
Name: Charles Sermon
 
Title Director
     
Date: March 13, 2019
PHASE4 VENTURES III GP LP
     
 
By: Phase4 Ventures III General Partner Limited,
 
its general partner
     
 
By:
 /s/ Charles Sermon
 
Name: Charles Sermon
 
Title Director
     
Date: March 13, 2019
PHASE4 VENTURES III GENERAL PARTNER
 
LIMITED
     
 
By:
 /s/ Charles Sermon
 
Name: Charles Sermon
 
Title Director
     
Date: March 13, 2019
 /s/ Alastair McKinnon
 
Alastair McKinnon
     
Date: March 13, 2019
 /s/ Denise Scots-Knight
 
Denise Scots-Knight
     
Date: March 13, 2019
 /s/ Charles Sermon
 
Charles Sermon



Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Albireo Pharma Charts.

Albireo Pharma (NASDAQ:ALBO)
Intraday Stock Chart

Today : Friday 13 December 2019

Click Here for more Albireo Pharma Charts.

Latest ALBO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.